Protara Therapeutics
Market cap $143M 61.6M shares (10-Q, Nov 3, 2026) × $2.32 close Nov 17, 2026
Most recent annual filing: 2026-03-10
- IV Choline Chloride Ph3 interim4Q 2026IV Choline Chloride Ph3 interim, 4Q 2026, material
- TARA-002 NMIBC enrollment done4Q 2026TARA-002 NMIBC enrollment done, 4Q 2026, notable
- TARA-002 Lymphatic Malformations enrollment done1Q 2027TARA-002 Lymphatic Malformations enrollment done, 1Q 2027, routine
- TARA-002 BLA filing2H 2027TARA-002 BLA filing, 2H 2027, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (3 active programs)
IV Choline Chloride
choline chlorideCapital (as filed)
- Cash
- $25.1M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $102M Sep 30, 2026
- Long-term investments
- $16.0M Sep 30, 2026
- Operating cash flow
- −$18.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $143M cash per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Offering documents (2)
- 2026-05-28 424B5 · At-the-market program up to $100M
- 2026-05-14 S-3 · Shelf registration up to $111M aggregate
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (11)
- 2026-11-17 UPDATE: Protara Therapeutics (TARA) - The Anchor Holder Is Gone 🔒 Paid
- 2026-11-07 UPDATE: Protara Therapeutics (TARA) - Buying the Factory 🔒 Paid
- 2026-08-12 UPDATE: Protara Therapeutics (TARA) - ADVANCED-3 Stops Being a Phase 3 🔒 Paid
- 2026-06-30 UPDATE: Protara Therapeutics (TARA) - The CMO Walks on Warrant Deadline Day 🔒 Paid
- 2026-05-16 UPDATE: Protara Therapeutics (TARA) - The BCG-Naïve 12-Month Holds 🔒 Paid
- 2026-05-15 UPDATE: Protara Therapeutics (TARA) - The ATM Goes Live 🔒 Paid
- 2026-05-14 UPDATE: Protara Therapeutics (TARA) - Q1 2026 Status Check 🔒 Paid
- 2026-04-27 UPDATE: Protara Therapeutics (TARA) - The Warrant Trigger Trips 🔒 Paid
- 2026-03-15 UPDATE: Protara Therapeutics (TARA) - FY25 Earnings 🔒 Paid
- 2026-03-01 UPDATE: Protara Therapeutics (TARA) - ASCO GU Update 🔒 Paid
- 2026-02-23 Protara Therapeutics (TARA): Scientific Deep Dive for Lead and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (11 calls)
Every verdict Biotech Distilled has published on Protara Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-02-23 Buy speculative Protara Therapeutics (TARA): Scientific Deep Dive for Lead and Pipeline Products Downside cushioned by fortress balance sheet and cash runway into 2028, with near-term upside from Q1 2026 BCG-Unresponsive data readout and PRV optionality from LM program.
- 2026-03-01 Buy speculative UPDATE: Protara Therapeutics (TARA) - ASCO GU Update ASCO GU data showed 33.3% 12-month CR clearing the FDA's ~30% regulatory floor with pristine safety profile; thesis intact with downside still protected by cash runway into 2028.
- 2026-03-15 Speculative buy speculative UPDATE: Protara Therapeutics (TARA) - FY25 Earnings $198M cash position removes financing overhang ahead of critical inflection points, but the repurposed biological pipeline carries inherent speculative risk.
- 2026-04-27 Speculative buy speculative UPDATE: Protara Therapeutics (TARA) - The Warrant Trigger Trips 68.0% six-month CR across 25 patients confirms data integrity; warrant mechanics and authorized-share expansion are flags to watch but do not break the thesis.
- 2026-05-14 Speculative buy speculative UPDATE: Protara Therapeutics (TARA) - Q1 2026 Status Check LM BLA on 2H 2027 timeline is most concrete the PRV thesis has been, but faster-than-modeled cash burn and CEO's expanded 10b5-1 selling plan are new watch items.
- 2026-05-15 Speculative buy speculative UPDATE: Protara Therapeutics (TARA) - The ATM Goes Live Clinical thesis unchanged but $100M ATM with TD Cowen means the 'no dilutive raise' selling point from the original BUY case no longer applies.
- 2026-05-16 Speculative buy speculative UPDATE: Protara Therapeutics (TARA) - The BCG-Naïve 12-Month Holds BCG-Naïve 55% 12-month CR with 91.7% nine-to-twelve-month durability fully underwrites ADVANCED-3 design; sell-off driven by ATM overhang, not clinical deterioration.
- 2026-06-30 Speculative buy speculative UPDATE: Protara Therapeutics (TARA) - The CMO Walks on Warrant Deadline Day CMO departure is a flag not a fire, but combined with ATM, CEO selling plan, and warrants expiring worthless, governance/financing noise has been louder than clinical signal for six weeks.
- 2026-08-12 Speculative buy speculative UPDATE: Protara Therapeutics (TARA) - ADVANCED-3 Stops Being a Phase 3 ADVANCED-3 redesigned from registrational Phase 3 to open-label exploratory trial, reducing the NMIBC thesis to a single-arm cohort; clinical data unchanged but structural bull case narrowed.
- 2026-11-07 Speculative buy speculative UPDATE: Protara Therapeutics (TARA) - Buying the Factory Acquiring Novex de-risks CMC manufacturing, but STARBORN-1 slipped a quarter, BLA language softened, and stock trades near cash value suggesting market expects dilution.
- 2026-11-17 Speculative buy speculative UPDATE: Protara Therapeutics (TARA) - The Anchor Holder Is Gone Janus Henderson fully exited its 9.6% anchor position during the slide, a negative conviction signal, but supply overhang is now cleared and stock still trades near cash value ahead of Q4 catalysts.
- Long call · opened Feb 23, 2026 at $7.43 · -68.8% vs XBI +14.4% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (6 quotes from 2 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“The Company remains on track to report interim results from the Phase 2b portion of THRIVE-3 in the fourth quarter of 2026.”
matched to IV Choline Chloride · interim data -
“Mr. Shefferman added, “Turning to our rare disease pipeline, we now expect to complete enrollment of the registrational STARBORN-1 trial of TARA-002 in LMs early in the first quarter of 2027.”
matched to TARA-002 (Lymphatic Malformations BLA) · regulatory submission
-
-
-
“We anticipate reporting interim results from the dose-confirmation portion of the trial in the fourth quarter of 2026.”
matched to IV Choline Chloride · interim data -
“We intend to provide an update on STARBORN-1 and complete enrollment of STARBORN-1 in the fourth quarter of 2026.”
matched to TARA-002 (Lymphatic Malformations) · enrollment complete -
“We expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in the fourth quarter of 2026.”
matched to TARA-002 (NMIBC, BCG-Unresponsive) · enrollment complete -
““We continue to make progress in the ADVANCED-2 trial and expect to complete enrollment in the fourth quarter of 2026.”
matched to TARA-002 (NMIBC, BCG-Unresponsive) · enrollment complete
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (26)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Apr 27, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 6, 2026ReleaseProtara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update→ BD updateSummary on the 8-K
- Nov 6, 20268-KCurrent report: results of operations · EX-99.1 PRESS RELEASE DATED NOVEMBER 6, 2026, ISSUED BY THE REGISTRANT→ BD updateProtara just bought its own manufacturing facility for $8.75M, completed THRIVE-3 Phase 2b enrollment with interim data due by year-end, and confirmed ADVANCED-2 BCG-Unresponsive enrollment wraps Q4 — a dense catalyst stack into a name trading at ~41% below the post-ASCO close.
- Nov 6, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 15, 2026ReleaseProtara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support
- Sep 8, 2026ReleaseProtara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Aug 11, 2026ReleaseProtara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business UpdateBD extracted 1 program update from this document → TARA pipeline
- Aug 11, 20268-KCurrent report: results of operations · EX-99.1 PRESS RELEASE DATED AUGUST 11, 2026, ISSUED BY THE REGISTRANTBD extracted 1 program update from this document → TARA pipeline
- Aug 11, 202610-QQuarterly report
- Jun 29, 20268-KCurrent report: officer / director change
- Jun 15, 20268-KCurrent report: shareholder vote
- May 28, 2026424B5Prospectus supplement (offering)
- May 20, 2026ReleaseProtara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
- May 18, 2026ReleaseProtara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
- May 15, 2026ReleaseProtara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
- May 14, 2026S-3Shelf registration
- May 13, 2026ReleaseProtara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
- May 13, 20268-KCurrent report: results of operations · EX-99.1 PRESS RELEASE DATED MAY 13, 2026, ISSUED BY THE REGISTRANT
- May 13, 202610-QQuarterly report
- Apr 28, 2026DEFA14AProxy soliciting material
- Apr 28, 2026DEF 14AProxy statement
- Apr 27, 2026ReleaseProtara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
- Apr 27, 2026ReleaseINVESTOR OVERVIEW
- Mar 30, 20268-KCurrent report: Reg FD disclosure
- Mar 10, 20268-KCurrent report: results of operations · EX-99.1 PRESS RELEASE DATED MARCH 10, 2026, ISSUED BY THE REGISTRANT
- Mar 10, 202610-KAnnual report
- Mar 6, 2026424B7Prospectus supplement
12 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment→ BD updateJanus Henderson, the anchor institutional holder I've tracked since the original deep dive at ~10–11%, has fully exited TARA as of September 30 — filing a 0-share 13G/A today while the stock sits at $2.38 and near its cash floor.
- Aug 13, 2026SCHEDULE 13G/A13G amendment
- Aug 11, 2026S-8Employee plan registration
- Jul 7, 2026SCHEDULE 13G/A13G amendment
- May 22, 2026EFFECTRegistration effective
- May 20, 2026CORRESPCORRESP
- May 19, 2026UPLOADUPLOAD
- May 15, 2026SCHEDULE 13G/A13G amendment
- Apr 28, 2026ARSAnnual report to shareholders
- Apr 27, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 17, 2026PRE 14APRE 14A
- Mar 2, 2026SCHEDULE 13GPassive >5% holder (13G)